Angiotech's corporate partner, Boston Scientific, announces first human use of TAXUS(R) Petal(TM) Bifurcation Stent
18 Juli 2007 - 11:59PM
PR Newswire (US)
VANCOUVER, July 18 /PRNewswire-FirstCall/ -- Angiotech
Pharmaceuticals, Inc. (NASDAQ:ANPINASDAQ:TSX:NASDAQ:ANP), a global
specialty pharmaceutical and medical device company, along with its
corporate partner Boston Scientific Corporation "BSC" (NYSE:BSX),
announced the successful implantation of BSC's TAXUS(R) Petal(TM)
Bifurcation Paclitaxel-Eluting Stent System (TAXUS Petal Stent) in
a patient in New Zealand, marking the beginning of the TAXUS PETAL
I First Human Use (FHU) Trial. The trial is designed to evaluate
the safety of a dedicated bifurcation paclitaxel-eluting stent
platform for the treatment of coronary artery disease. The
procedure was performed by John Ormiston, M.D., at Auckland City
Hospital in Auckland, New Zealand. A significant percentage of
coronary artery disease - as much as 30 percent - occurs at a
bifurcation, where one artery branches into two smaller arteries
(one being the continuation of the main branch and the other often
referred to as the side branch). Bifurcations present a common
location for the build-up of plaque and are particularly difficult
to treat with currently available stents. Conventional coronary
stents were designed to treat tubular arteries and are considered
less than optimal for the y-shaped anatomy of a bifurcation. The
TAXUS Petal Stent is designed specifically to treat both the main
branch and the side branch of a bifurcation. The TAXUS Petal Stent
consists of a traditional drug-eluting stent with an innovative
side structure (the Petal Strut) in the middle of the stent that
opens into the side branch. The TAXUS Petal is designed to provide
access, coverage and support to the critical areas of the
bifurcation and uses a proprietary platinum chromium alloy.
Platinum chromium is designed to offer an improvement over
stainless steel and cobalt chromium, enabling even thinner struts,
increased flexibility and improved radiopacity. The TAXUS Petal
Stent is coated with the proven, market-leading combination of the
Paclitaxel drug and Translute(TM) polymer. "The TAXUS Petal Stent
enabled us to successfully treat a patient with a difficult
bifurcation (coronary branch point) stenosis. Bifurcations are a
major challenge in interventional cardiology, and the development
of a dedicated drug-eluting bifurcation stent is an important
advancement," said Dr. Ormiston, the principal investigator for the
TAXUS Petal I FHU Trial. "A major strength of the TAXUS Petal Stent
design is to provide consistent mechanical support and drug
application not only to the main branch but also to the side-branch
ostium, where renarrowing is common with other techniques used
today." The TAXUS PETAL I FHU clinical trial is a non-randomized
study with an initial assessment of acute performance and safety
(death, myocardial infarction, target vessel revascularization) at
30 days and six months, as well as continued annual follow-up for
five years. TAXUS PETAL I FHU will enroll a total of 45 patients in
New Zealand, France and Germany. Upon successful completion of this
study, BSC intends to begin a pivotal trial to gain U.S. and
international approval for the commercialization of the TAXUS Petal
Stent. "We are excited by the start of the TAXUS PETAL I FHU Trial
and the fact that our paclitaxel technology may offer a solution to
bifurcations, which is an area in coronary stenting that remains
challenging for physicians," said Dr. William Hunter, President and
CEO of Angiotech. The TAXUS Petal Stent is under development and
not available for sale. Note on Forward Looking Statements
Statements contained in this press release that are not based on
historical fact, including without limitation statements containing
the words "believes," "may," "plans," "will," "estimate,"
"continue," "anticipates," "intends," "expects" and similar
expressions, constitute "forward-looking statements" within the
meaning of the U.S. Private Securities Litigation Reform Act of
1995 and constitute "forward-looking information" within the
meaning of applicable Canadian securities laws. All such statements
are made pursuant to the "safe harbor" provisions of applicable
securities legislation. Such forward-looking statements involve
known and unknown risks, uncertainties and other factors that may
cause the actual results, events or developments to be materially
different from any future results, events or developments expressed
or implied by such forward-looking statements. Many such risks,
uncertainties and other factors are taken into account as part of
our assumptions underlying these forward-looking statements and
include, among others, the following; general economic and business
conditions, both nationally and in the regions in which we operate;
market demand; technological changes that could impact our existing
products or our ability to develop and commercialize future
products; competition; existing governmental regulations and
changes in, or the failure to comply with, governmental
regulations; decisions, and the timing of decisions, made by health
regulatory agencies regarding approval of our technology and
products and decisions regarding reimbursement where applicable;
the requirement for substantial funding to conduct research and
development and to expand commercialization activities; and any
other factors that may affect performance. In addition, our
business is subject to certain operating risks that may cause the
actual results expressed or implied by the forward-looking
statements in this report to differ materially from our actual
results. These operating risks include; poor performance of the
product in the clinical setting; adverse events related to the use
of the product; improper estimation of the size of the product
markets; adverse results or unexpected delays in clinical
development processes; our ability to attract and retain qualified
personnel; our ability to successfully complete preclinical and
clinical development of our products; changes in business strategy
or development plans; our failure to obtain patent protection for
discoveries; loss of patent protection resulting from third party
challenges to our patents; commercialization limitations imposed by
patents owned or controlled by third parties; our ability to obtain
rights to technology from licensors; liability for patent claims
and other claims asserted against us; our ability to obtain and
enforce timely patent and other intellectual property protection
for our technology and products; the ability to enter into, and to
maintain, corporate alliances relating to the development and
commercialization of our technology and products; market acceptance
of our technology and products; our ability to successfully
manufacture, market and sell our products; the continued
availability of capital to finance our activities; our ability to
continue to integrate into our business the operations of American
Medical Instruments Holdings, Inc. and our ability to achieve the
operational and other synergies and the other commercial or
financial benefits expected as a result of that acquisition; and
any other factors referenced in our annual information form and
other filings with the applicable Canadian securities regulatory
authorities or the SEC. Given these uncertainties, assumptions and
risk factors, readers are cautioned not to place undue reliance on
such forward-looking statements. We disclaim any obligation to
update any such factors or to publicly announce the result of any
revisions to any of the forward-looking statements contained in
this prospectus to reflect future results, events or developments.
BSC acquired worldwide exclusive rights from Angiotech to use
paclitaxel to coat its coronary stent products and has co-exclusive
rights to certain peripheral vascular and non-vascular products.
(R), (TM) Trademarks of Boston Scientific Corporation About
Angiotech Angiotech Pharmaceuticals, Inc. is a global specialty
pharmaceutical and medical device company with over 1,500 dedicated
employees. Angiotech discovers, develops and markets innovative
treatment solutions for diseases or complications associated with
medical device implants, surgical interventions and acute injury.
To find out more about Angiotech
(NASDAQ:ANPINASDAQ:TSX:NASDAQ:ANP), please visit our website at
http://www.angiotech.com/. CONTACT: Jodi Regts, Manager, Investor
Relations and Corporate Communications, Angiotech Pharmaceuticals,
Inc., (604) 221-7930, DATASOURCE: Angiotech Pharmaceuticals, Inc.
CONTACT: Jodi Regts, Manager, Investor Relations and Corporate
Communications, Angiotech Pharmaceuticals, Inc., (604) 221-7930,
Copyright
Angiotech Pharmaceuticals - Common Shares (MM) (NASDAQ:ANPI)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Angiotech Pharmaceuticals - Common Shares (MM) (NASDAQ:ANPI)
Historical Stock Chart
Von Jul 2023 bis Jul 2024